PolyPid Provides Corporate Update and Reports First Quarter 2023 Financial Results

Submitted Revised Protocol for SHIELD II Phase 3 Trial to FDA to Evaluate D-PLEX 100 for Prevention of Abdominal Colorectal Surgical Site Infections ; Recruitment Expected to Re sume Imminently Received Advice from the Swedish Medical Products Agency Consistent with Feedback Received